图片来源:Guardant Health官网
药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务,服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求,欢迎点击下方图片填写具体信息。
▲如您有任何业务需求,请长按扫描上方二维码,或点击文末“阅读原文/Read more”,即可访问业务对接平台,填写业务需求信息
参考资料:
[1] Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations. Retrieved August 12, 2022 from https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-Receives-FDA-Approval-for-Guardant360-CDx-as-Companion-Diagnostic-for-Daiichi-Sankyo-and-AstraZenecas-ENHERTU-for-Treatment-of-NSCLC-Patients-With-Activating-HER2-Mutations/default.aspx
[2] HOW DO YOU TREAT AT THE SPEED OF CANCER? The answers are in our blood. Retrieved August 12, 2022 from https://guardant360cdx.com/
[3] FDA Approves First NGS-Based Companion Diagnostic to Aid in Selecting Non-Small Cell Lung Cancer Patients with HER2 (ERBB2) Activating Mutations (SNVs & Exon 20 Insertions) for Treatment with ENHERTU. Retrieved August 12, 2022 from https://www.biospace.com/article/releases/fda-approves-first-ngs-based-companion-diagnostic-to-aid-in-selecting-non-small-cell-lung-cancer-patients-with-her2-erbb2-activating-mutations-snvs-and-amp-exon-20-insertions-for-treatment-with-enhertu/